CD38 and Miyoshi myopathy: Furthermore, MEDI2228 was found to elevate CD38 expression on MM cells through an INF-driven immune response, counteracting the CD38 downregulation or absence in daratumumab-resistant MM cells, thus potentiating daratumumab’s efficacy [37].